



## Covid-19: Medicines Criticality Assessment Group

via teleconference

Actions – from Tuesday, 28th April 2020

### Open Actions

No	Action Detail	Owner	By When	Latest Update	Status
1	Use of anti-coagulants.	AHDMP		Updated VTE guidance published on Thursday. Work continues on two other documents for different patient cohorts but with significant overlap: anticoagulant requirements for more critical Covid patients and Nephrology requirements due to hypercoagulation.  HSE National Quality Improvement to share communication regarding prophylaxis with HPRA.	Open
2	European industry-led study on ICU meds demand	HPRA & DoH		HPRA update: Overlap between industry-led study and JP has been flagged. Concerns about industry approach to be discussed in upcoming European meetings. HPRA hope to have updated information following the European Steering Group meeting on Friday.	Open
3	Report on Meds CAG progress to date to be drafted.	DoH		Agreement that it is timely to undertake review. DoH issued a draft document to the group; group members to review and submit observations by COB Thursday 20th April.	Open
4	Department of Health to look into how information on approved clinical trials can be shared with local clinicians and/or Meds CAG	DoH		DoH and HPRA to discuss how this can be progressed	Open



5	Awaiting HIQA clarification to inform guidelines for nursing homes in relation to storage of small stock of emergency medicines.	HSE National Quality Improvement/DoH		HSE National Quality Improvement has written to, HIQA. Department of Health has asked for DOH line unit to engage with HIQA on matter	Open
6	Department of Health to share with PCRS the list of products banned by France for export.	DoH		Draft document submitted for review. Will be shared by DoH to group once reviewed internally.	Open
7	Research Subgroup of EAG to reply to comments submitted	Prof. Bergin		Prof. Bergin as co-chair acknowledged the comments and said that they had been noted by the sub-group, however the paper had already been submitted to NPHE. Decision from NPHE pending. Prof. Bergin to formally write back to MCAG	Open

### Ongoing actions

No	Action Detail	Owner	Latest Update	Status
1	Monitoring of supplies of medicines:		No significant updates	Open
A	-used in Irish hospitals that may be used to treat Covid 19.	AHDMP,	Slight improvement in supply of previously critical products. Suppliers are requesting replenishment in excess of normal numbers to improve situation further.	
B	-used in Irish hospitals to treat secondary infections and provide supportive care	AHDMP	AHDMP receiving updates from wholesalers on where products were supplied to hospitals over previous 2 months. No signals to suggest any need to redistribute stock between hospitals.  Waiting on CION response to submission to ICU Joint Procurement.	



C	-used in wider hospital system	AHDMP, NCCP and PCRS	Through its engagements with wholesaler/ MAHs, HPRA note a decrease in order volumes, indicating a decrease in overall use. Any reopening of services would need to be carefully managed to avoid a rebound effect; a sudden increase in demand which could precipitate logistical and localised supply issues	
D	- in primary care	PCRS and HPRA	PCRS updated table of respiratory medicines and antimicrobials. Continue to monitor midazolam supply closely	
2	Supply of neuromuscular blockers	AHDMP	NMBAs to remain at amber, over the coming weeks, barring a sharp increase in ICU occupancy.  Some indications of change in prescriber behavior based on uptake of alternative moieties, especially rocuronium. Of no significant improvement. Department of Health to see could Meds. Group present to clinical leadership forum on the above.  Mechanism for flagging potential local shortages to be considered by AHDMP  <b>[RISK MITIGATION OUTLINED BELOW]</b>	Open



Neuromuscular blocking agents – increased global demand and limited availability				
Risk Mitigation Strategy			Action Owner	Risk Status
Support prescribing of the therapeutic class, not just one moiety within the class			Critical Care Programme and Prescribers	Medium
Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured			AHDMP	Medium
Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply			AHDMP/HPRA	Medium
Escalation of European wide supply chain vulnerability to EU Commission			DOH	Medium
3	PCRS to update Group on mechanism to limit <i>de novo</i> patients on hydroxychloroquine for antiviral purposes	PCRS	Small numbers of prescriptions coming through. Limited checks on usage sufficient in controlling dispensing rates.	Open
4	Updates from Irish Epidemiological Modelling Advisory Group	DoH	Reply issued to Irish Epidemiological Modelling Advisory Group, expressing thanks and seeking regular updates and some follow up questions.	Open
5	Monitoring of parallel export activities	HPRA		Open

**Decisions: NONE**

### Closed Actions:

6	Parallel exporting	HPRA	All secondary wholesalers known to supply outside of Ireland have been contacted. Correspondence continues in order to ensure alignment across all parties and to review April's data.	Closed
9	Export prohibitions	HPRA/ DOH	Email has been sent from DoH to UK's Department of Health and Social Care in order to open discussion on application of restrictions.	Closed